Figure 4From: Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathwaySorafenib in combination with vitamin K1 (VK1) inhibits phospho-mitogen-activated protein kinase kinase (MEK) and phospho-extracellular signal-regulated kinase (ERK) in BT325 (A) and U251 (B) cells. Cells were treated with sorafenib (2.5 μM), VK1 (50 μM), or their combination for 24 h.Back to article page